2021 Investor Information

Investor Materials

ANNUAL REPORT

View an enhanced version of our Annual Report.

PROXY STATEMENT

View an enhanced version of our  Proxy Statement. 

REQUEST PAPER MATERIALS

Request paper copies of the above proxy materials online now, by email or by phone by dialing 866-648-8133.

VOTE ONLINE

Your vote is IMPORTANT!

Please vote your proxy online now or by phone by dialing 866-206-4393. 

ANNUAL MEETING

DATE

August 18, 2021

TIME 

10:00 AM ET

VIRTUAL MEETING

To Register for the Meeting



Deadline to Register*
August 17, 2021 
5:00 PM ET  

*Note: You must register by the deadline to be eligible to participate in the meeting.

ABOUT US

NeuBase Therapeutics, Inc., is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.

The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOLâ„¢) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.


Copyright © 2021 Mediant Communications Inc.
All Rights Reserved.